Top

Digestive Diseases and Sciences

Published in:

01-02-2013 | Original Article

Egr-1 Promotes Cell Proliferation and Invasion by Increasing β-Catenin Expression in Gastric Cancer

Authors: Ting Sun, Hua Tian, Yu-Guang Feng, Ya-Qin Zhu, Wei-Qian Zhang

Published in: Digestive Diseases and Sciences | Issue 2/2013

Abstract

Background

Abnormal expression of early growth response gene 1 (Egr-1) and β-catenin may play a crucial role in the development and progression of human cancer. However, little is known about the expression and underlying molecular mechanisms in which Egr-1 and β-catenin are involved in the development and progression of gastric cancer.

Aims

The purpose of this study was to elucidate the potential relationship between Egr-1 and β-catenin expression in gastric cancer, which contributes to finding new molecular carcinogenesis as a potential therapeutic target for gastric cancer.

Methods

In a sample of 102 cases of human gastric cancer, the expression of Egr-1 and β-catenin was detected using immunohistochemistry. Egr-1 gene was transfected into gastric cancer SGC7901 cells and its role in proliferation and cell invasion was detected by MTT assay, flow cytometry, wound-healing and transwell invasion assay. Western blot analysis was used to study the expression of β-catenin and cyclin D1 proteins.

Results

Upregulated Egr-1 and β-catenin protein expression were strongly correlated with cancer progression and depth of invasion in gastric cancer. β-catenin, present mainly in cytoplasmic and nucleus of gastric cancer cells, was also positively correlated with Egr-1 expression in gastric cancer. Furthermore, the overexpression of Egr-1 upregulated β-catenin expression level, promoted cell proliferation, increased cell population in S-phase and enhanced gastric cancer cell migration and invasion in vitro.

Conclusions

Egr-1 might contribute to gastric cancer proliferation and invasion through activation of the β-catenin signaling pathway.

Baron V, Adamson ED, Calogero A, Ragona G, Mercola D. The transcription factor Egr1 is a direct regulator of multiple tumor suppressors including TGFbeta1, PTEN, p53, and fibronectin. Cancer Gene Ther. 2006;13:115–124.PubMedCrossRef

Adamson E, de Belle I, Mittal S, et al. Egr1 signaling in prostate cancer. Cancer Biol Ther. 2003;2:617–622.PubMed

Abdulkadir SA. Mechanisms of prostate tumorigenesis: roles for transcription factors Nkx3.1 and Egr1. Ann N Y Acad Sci. 2005;1059:33–40.PubMedCrossRef

Virolle T, Krones-Herzig A, Baron V, De Gregorio G, Adamson ED, Mercola D. Egr1 promotes growth and survival of prostate cancer cells. Identification of novel Egr1 target genes. J Biol Chem. 2003;278:11802–11810.PubMedCrossRef

Sauer L, Gitenay D, Vo C, Baron VT. Mutant p53 initiates a feedback loop that involves Egr-1/EGF receptor/ERK in prostate cancer cells. Oncogene. 2010;29:2628–2637.PubMedCrossRef

Boone DN, Qi Y, Li Z, Hann SR. Egr1 mediates p53-independent c-Myc induced apoptosis via a non canonical ARF-dependent transcriptional mechanism. Proc Natl Acad Sci USA. 2011;108:632–637.PubMedCrossRef

Shareef MM, Cui N, Burikhanov R, Gupta S, Satishkumar S, et al. Role of tumor necrosis factor-alpha and TRAIL in high-dose radiation-induced bystander signaling in lung adenocarcinoma. Cancer Res. 2007;67:11811–11820.PubMedCrossRef

Kobayashi D, Yamada M, Kamagata C, et al. Overexpression of early growth response-1 as a metastasis-regulatory factor in gastric cancer. Anticancer Res. 2002;22:3963–3970.PubMed

Giles RH, van Es JH, Clevers H. Caught up in a Wnt storm: Wnt signaling in cancer. Biochim Biophys Acta. 2003;1653:1–24.PubMed

10.

Takasu S, Tsukamoto T, Cao XY, et al. Roles of cyclooxygenase-2 and microsomal prostaglandin E synthase-1 expression and beta-catenin activation in gastric carcinogenesis in N-methyl-N-nitrosourea-treated K19–C2mE transgenic mice. Cancer Sci. 2008;99:2356–2364.PubMedCrossRef

11.

Yoon CS, Hyung WJ, Lee JH, et al. Expression of S100A4, E-cadherin, alpha- and beta-catenin in gastric adenocarcinoma. Hepatogastroenterology. 2008;55:1916–1920.PubMed

12.

Dvory-Sobol H, Sagiv E, Liberman E, Kazanov D, Arber N. Suppression of gastric cancer cell growth by targeting the beta-catenin/T-cell factor pathway. Cancer. 2007;109:188–197.PubMedCrossRef

13.

Dvory-Sobol H, Sagiv E, Kazanov D, Ben-Ze’ev A, Arber N. Targeting the active beta-catenin pathway to treat cancer cells. Mol Cancer Ther. 2006;5:2861–2871.PubMedCrossRef

14.

de Belle I, Huang RP, Fan Y, Liu C, Mercola D, Adamson ED. p53 and Egr-1 additively suppress transformed growth in HT1080 cells but Egr-1 counteracts p53-dependent apoptosis. Oncogene. 1999;18:3633–3642.PubMedCrossRef

15.

Yu J, Zhang SS, Saito K, et al. PTEN regulation by Akt-EGR1-ARF-PTEN axis. EMBO J. 2009;28:21–33.PubMedCrossRef

16.

Kim J, Lee YH, Kwon TK, Chang JS, Chung KC, Min DS. Phospholipase D prevents etoposide-induced apoptosis by inhibiting the expression of early growth response-1 and phosphatase and tensin homologue deleted on chromosome 10. Cancer Res. 2006;66:784–793.PubMedCrossRef

17.

Mahalingam D, Natoni A, Keane M, Samali A, Szegezdi E. Early growth response-1 is a regulator of DR5-induced apoptosis in colon cancer cells. Br J Cancer. 2010;102:754–764.PubMedCrossRef

18.

Shtutman M, Zhurinsky J, Simcha I, et al. The cyclin D1 gene is a target of the beta-catenin/LEF-1 pathway. Proc Natl Acad Sci USA. 1999;96:5522–5527.PubMedCrossRef

19.

Gnad T, Feoktistova M, Leverkus M, Lendeckel U, Naumann M. Helicobacter pylori-induced activation of beta-catenin involves low density lipoprotein receptor-related protein 6 and dishevelled. Mol Cancer. 2010;9:31.PubMedCrossRef

20.

Lee SH, Kang HJ, Shin DH, et al. Expression of beta-catenin and its mechanism of delocalization in intestinal-type early gastric cancer based on mucin expression. Histol Histopathol. 2009;24:831–838.PubMed

21.

Saegusa M, Hashimura M, Kuwata T, et al. Transcription factor Egr1 acts as an upstream regulator of beta-catenin signalling through up-regulation of TCF4 and p300 expression during trans-differentiation of endometrial carcinoma cells. J Pathol. 2008;216:521–532.PubMedCrossRef

Title: Egr-1 Promotes Cell Proliferation and Invasion by Increasing β-Catenin Expression in Gastric Cancer
Authors: Ting Sun
Hua Tian
Yu-Guang Feng
Ya-Qin Zhu
Wei-Qian Zhang
Publication date: 01-02-2013
Publisher: Springer US
Published in: Digestive Diseases and Sciences / Issue 2/2013
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI: https://doi.org/10.1007/s10620-012-2356-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Background

Aims

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 2/2013

The Neglected Cousin of the Hepatocyte: How Gallbladder Epithelial Cells Might Contribute to Cholesterol Gallstone Formation

Technical Feasibility and Revision Efficacy of the Sequential Deployment of Endoscopic Bilateral Side-by-Side Metal Stents for Malignant Hilar Biliary Strictures: A Multicenter Prospective Study

The Association Between Reflux Esophagitis and Psychosocial Stress

CD36 mRNA in the Gastrointestinal Tract Is Differentially Regulated by Dietary Fat Intake in Obesity-Prone and Obesity-Resistant Rats

Allostasis in Nonalcoholic Fatty Liver Disease: Implications for Risk Assessment

Pharmacodynamic and Clinical Endpoints for Functional Colonic Disorders: Statistical Considerations

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials